Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus.
10.1016/j.apsb.2023.09.004
- Author:
Jiamei LE
1
;
Yilong CHEN
2
;
Wei YANG
3
;
Ligong CHEN
4
;
Jianping YE
3
Author Information
1. Shanghai Key Laboratory of Molecular Imaging, Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
2. School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China.
3. Metabolic Disease Research Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, China.
4. School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China.
- Publication Type:Review
- Keywords:
ATP production;
Energy metabolism;
Glucose homeostasis;
Polymorphisms;
Solute carriers (SLCs);
Type 2 diabetes mellitus (T2DM)
- From:
Acta Pharmaceutica Sinica B
2024;14(2):437-454
- CountryChina
- Language:English
-
Abstract:
Solute carriers (SLCs) constitute the largest superfamily of membrane transporter proteins. These transporters, present in various SLC families, play a vital role in energy metabolism by facilitating the transport of diverse substances, including glucose, fatty acids, amino acids, nucleotides, and ions. They actively participate in the regulation of glucose metabolism at various steps, such as glucose uptake (e.g., SLC2A4/GLUT4), glucose reabsorption (e.g., SLC5A2/SGLT2), thermogenesis (e.g., SLC25A7/UCP-1), and ATP production (e.g., SLC25A4/ANT1 and SLC25A5/ANT2). The activities of these transporters contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). Notably, SLC5A2 has emerged as a valid drug target for T2DM due to its role in renal glucose reabsorption, leading to groundbreaking advancements in diabetes drug discovery. Alongside SLC5A2, multiple families of SLC transporters involved in the regulation of glucose homeostasis hold potential applications for T2DM therapy. SLCs also impact drug metabolism of diabetic medicines through gene polymorphisms, such as rosiglitazone (SLCO1B1/OATP1B1) and metformin (SLC22A1-3/OCT1-3 and SLC47A1, 2/MATE1, 2). By consolidating insights into the biological activities and clinical relevance of SLC transporters in T2DM, this review offers a comprehensive update on their roles in controlling glucose metabolism as potential drug targets.
